Nevertheless, the essential nature of SETD8 makes it even more important to have a good understanding of what are the determinants of sensitivity to SETD8 inhibitors, so that the use of these drugs is directed to cancer patients with mutations that make them more likely to respond. The gene discussed is KMT5A; the disease is cancer.